157014-35-2

Usage

Uses

Used in Organic Synthesis:
2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE is used as a reagent in organic synthesis for its ability to participate in a wide range of chemical reactions. Its presence of a bromine atom allows for various substitution and coupling reactions, while the fluorine atom can be involved in fluorination processes. The methoxy group and phenyl ring provide additional sites for functionalization and structural diversity.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE is utilized as an intermediate in the synthesis of various drugs. Its unique structure contributes to the development of new pharmaceutical compounds with potential therapeutic properties. 2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE's reactivity and functional groups make it a valuable building block for creating complex drug molecules.
Used in Medicinal Chemistry Research:
2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE is of interest to researchers in medicinal chemistry due to its potential applications in the discovery and development of new drugs. Its structural features can be modified to explore the biological activity of related compounds, leading to the identification of novel therapeutic agents with improved efficacy and selectivity.
Used in Chemical Reactions as a Reagent:
In the field of chemical reactions, 2-BROMO-1-(2-FLUORO-4-METHOXYPHENYL)ETHANONE serves as a reagent that can be employed in various processes. Its bromine and fluorine atoms, along with the methoxy group, enable it to participate in a multitude of reactions, making it a valuable tool for chemists in synthesizing new compounds and exploring reaction mechanisms.

InChI:InChI=1/C9H8BrFO2/c1-13-6-2-3-7(8(11)4-6)9(12)5-10/h2-4H,5H2,1H3

Upstream product

• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 

Downstream Products

• 1026843-12-8 8-benzoyl-2-(2-fluoro-4-methoxy-phenyl)-6,7,8,9-tetrahydro-5H-1,3a,5,8-tetraaza-cyclopenta[a]naphthalen-4-one 
• 1314984-63-8 C₁₀H₉FN₂O 
• 1403674-85-0 2,3,5-tris(2-fluoro-4-methoxyphenyl)-1-propyl-1H-pyrrole 
• 1403674-84-9 2,5-bis(2-fluoro-4-methoxyphenyl)-3-(4-methoxyphenyl)-1-propyl-1H-pyrrole 
• 1403674-83-8 2,5-bis(2-fluoro-4-methoxyphenyl)-3-(4-methoxyphenyl)-1-methyl-1H-pyrrole 
• 1403674-77-0 5-(2-fluoro-4-methoxyphenyl)-2,3-bis(4-methoxyphenyl)-1-propyl-1H-pyrrole 
• 1403674-76-9 5-(2-fluoro-4-methoxyphenyl)-2,3-bis(4-methoxyphenyl)-1-methyl-1H-pyrrole 
• 1403674-89-4 C₂₅H₂₂FNO₃ 
• 1403674-88-3 C₂₃H₁₈FNO₃ 
• 1403674-97-4 C₂₅H₂₀F₃NO₃ 
• 1403674-96-3 C₂₅H₂₁F₂NO₃ 
• 1403674-95-2 C₂₃H₁₇F₂NO₃ 
• 1403674-73-6 1,2,4-tris(2-fluoro-4-methoxyphenyl)-butane-1,4-dione 
• 1403674-70-3 4-(2-fluoro-4-methoxyphenyl)-1,2-bis(4-methoxyphenyl)-butane-1,4-dione 

Relevant academic research and scientific papers

NEGATIVE ALLOSTERIC MODULATION OF GLUN3-CONTAINING N-METHYL-D-ASPARTATE RECEPTORS

Disclosed are negative allosteric modulators of GluN3-containing NMDA receptors. In general, these compounds are highly selective for GluN3 (such as GluN3A and/or GluN3B) over GluN1 and/or GluN2. They can function as non-competitive antagonists with activity that is independent of membrane potential, glycine concentration, and extracellular pH. Also disclosed are pharmaceutical formulations of the negative allosteric modulators. These compounds can be used to enhance synaptic function and/or treating a neurological condition or disorder. Exemplary neurological conditions or disorders include, but are not limited to, major mental disorders, conditions that involve basal ganglia or altered dopamine, substance abuse/addiction or predisposition to substance abuse/addiction, pain disorders, developmental delay or situations with impaired learning, memory, and/or cognition, acute neuronal or glial injuries, and circuit disorders.

Influence of chlorine or fluorine substitution on the estrogenic properties of 1-alkyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrroles

In continuation of our previous work, several 1-alkyl-2,3,5-tris(4- hydroxyphenyl)aryl-1H-pyrroles with chlorine or fluorine substituents in the aryl residues were synthesized and tested for estrogen receptor (ER) binding at isolated ERα/ERβ receptors (HAP assay) and in transactivation assays using ERα-positive MCF-7/2a as well as U2-OS/ERα and U2-OS/ERβ cells. In the competition experiment at ERα the compounds displayed very high relative binding affinities of up to 37% (determined for 8m) but with restricted subtype selectivity (e.g., ERα/ERβ (8m) = 9). The highest estrogenic potency in ERα-positive MCF-7/2a cells was determined for 2,3,5-tris(2-fluoro-4-hydroxyphenyl)-1-propyl-1H-pyrrole 8m (EC50 = 23 nM), while in U2-OS/ERα cells 2-(2-fluoro-4-hydroxyphenyl)-3,5-bis(4- hydroxyphenyl)-1-propyl-1H-pyrrole 8b (EC50 = 0.12 nM) was the most potent agonist, only 30-fold less active than estradiol (E2, EC50 = 0.004 nM). In U2-OS/ERβ cells for all pyrroles no transactivation could be observed, which indicates that they are selective ERα agonists in cellular systems.

Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain

A series of 2,4-diphenyl-1H-imidazole analogs have been synthesized and displayed potent human CB2 agonist activity. Many of these analogs showed high functional selectivity over human CB1 receptors. The syntheses, structure-activity relationships, and selected pharmacokinetic data of these analogs are described.

Pyrrole derivatives and medicinal composition

The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient. STR1 (wherein R1 represents hydrogen or alkoxycar91 bonylamino, R2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R3 represents cyano or carbamoyl; R4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted). The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.

Process for producing optically active carbinols

The present invention relates to a process for producing optically active halomethyl phenyl carbinols of the formula (1), comprising reducing halomethyl phenyl ketones of the formula (2) using an asymmetric reducing agent obtained from boranes and optically active α-phenyl-substituted-β-amino alcohols of the formula (3) or optically active α-non-substituted-β-amino alcohols of the formula (4). The present invention further relates to a process for producing optically active carbinols, comprising reacting a prochiral keytone with an asymmetric reducing agent obtained from optically active β-amino alcohols of the formula (5), a metal boron hydride and Lewis acid or lower dialkyl sulfuric acid. All of the formulas (1) to (5) are the same as shown in the specification.

Pharmaceutically active bicyclic-heterocyclic amines

The pharmaceutically active bicyclic heterocyclic amines (XXX) STR1 where W1 is --N= or --CH=; W3 is --N= or --CH=; W5 is --N= or --CR5 -- with the proviso that W5 is --CR5 -- when both W1 and W3 are --N= which are useful as pharmaceuticals in treating mild and/or moderate to severe head injury, subarachnoid hemorrhage and subsequent ischemic stroke, asthma and reduction of mucous formation/secretion in the lung and other diseases and injuries.